Health Research Registry List

Research Registry No : HRID-00344_V12
 
University Departmental Research :
 
Registration Date : 2019-05-17
 
Title of Research : Antihypertensive effect of Millingtonia hortensis Linn.f. leaves (Aykayit) on Stage 1 hypertensive patients
 
Principle Investigator : Khine Khine Lwin
 
Co-authors : May Aye Than, Thein Kyaw, Tin Tin Htay, Ko Ko Zaw, Khin Taryar Myint, Nu Nu Win and Win Win Maw.
 
Field of Research : Pharmacology
 
Publication Source : Myanmar Health Sciences Research Journal. 2014; 26(3): P207-213
 
 
Year of Publication : 2014
 
URL of Publication : www.myanmarhsrj.com
 
Presentation Source : 42nd Myanmar Health Research Congress. 2014; P53-54
 
Placement of Presentation : Department of Medical Research, Yangon
 
Year of Presentation : 2014
 
Abstract : This study was done to determine the antihypertensive effect of Millingtonia hortensis Linn.f. dried leave powder tablet on 16 (Stage 1) hypertensive patients attending the Outpatient Department of Traditional Medicine Hospital, Yangon. Study design was open type (single arm) study. After wash out period of 3 days, the patients were treated orally with dried leaves powder tablet (500 mg), 3 g three times daily for 4 weeks. Blood pressure was monitored at 0hr, 0.5 hr and hourly up to 6 hr after the first dose of the trial drug. Monitoring of blood pressure and vital signs were done on day 1, day 2, day 3 and weekly up to 4 weeks. Side effects were monitored on each patient follow up. Investigations of biochemical and hematological parameters (blood for complete picture, random blood sugar, Liver Function Test, Renal Function Test) and ECG were done before and at the end of the study. It was found that significant reduction of the mean supine blood pressure from baseline level was from 1 hr to 3 hr after the first dose of the trial drug. At the end of the trial , significant reductions in the mean supine systolic and diastolic blood pressures were found from 144.69± 5.62 mm Hg (baseline) to 130.94±8.21 mmHg (P<0.001) and 97.19± 6.82 mm Hg (base line) to 87.38 ±5.56 mmHg (P<0.001) respectively. The results of laboratory investigations were within the reference normal ranges. No side effects were observed. In conclusion, this drug possessed significant antihypertensive effect on stage 1 hypertensive patients with no side effects.
 
 
IRB/PRC/ERC Approval Date : 2008-06-16
 
Placement of IRB/PRC/ERC : Department of Medical Resesarch, Yangon
 
IRB/PRC/ERC Approval Letter/Document : IMG_0001.pdf
 
Pre-existing Registration ID : -
 
Pre-existing Name of Organization : -
 
Pre-existing Website : -